Panda and ABcann Medicinals Announce Multi-Stage Product Testing Methodology
OTTAWA, April 24, 2017 (GLOBE NEWSWIRE) — Panda Capital Inc. (NEX:PDA.H) (the “Company”) is pleased to announce details of the multi-stage product testing methodology at ABcann Medicinals Inc. (“ABcann”). As previously announced, the Company has entered into an amalgamation agreement pursuant to which the Company has agreed to acquire all of the outstanding securities of ABcann, a fully-licensed Canadian cannabis producer (the “Transaction”).
ABcann, which was awarded its cannabis production license from Canadian regulators in 2014, recognizes the essential value of Quality Assurance and has implemented a thorough and transparent process to maintain and achieve its industry-leading, organic process production standards. ABcann has prepared and carries out an exhaustive testing process for its cannabis production which combines internal testing procedures and external third party laboratory testing.
“ABcann is serving many different customers with varying expectations that rely on the company to complete accurate third party testing and independent evaluations, which we support in the industry,” says Ken Clement, founder of ABcann. “Our retail patient base demands top quality, organic processes and pesticide-free cannabis products. Our biotechnology customers must have quality and consistency down to the genetics level to complete their research which directly encompasses the medical community providing them the confidence in prescribing. For cannabis to be accepted as mainstream medicine, we knew we had to grow it standardized, batch after batch. It’s our job at ABcann to make that happen.”
To date, ABcann has met or exceeded all required industry standards as tested by its independent laboratories and is confident that by employing this rigorous testing methodology it will continue to meet these standards as it expands into higher volume production facilities. It is the Company’s priority that our customers continue to receive the consistent high quality tested products they have come to trust.
Ken Clement, founder of ABcann
ABcann’s Management Team has established stringent internal production guidelines. Our Quality Assurance Team enforces the mandatory guidelines to help achieve industry-leading standards for quality and consistency of cannabis production. ABcann is committed to consistent quality throughout the company and is in the process of achieving ISO 9001:2015 certification through BSI Group Canada.
ABcann’s Quality Assurance program also includes external third party testing through RPC, a laboratory services provider founded in 1962 and based in New Brunswick, Canada. RPC’s laboratory facilities in Fredericton and Moncton are accredited by Standards Council of Canada (SCC) to the ISO/IEC 17025:2005 laboratory standard and its accredited methods have long included microbial, metals, organic compounds, and pesticide tests for various matrices.
RPC’s operational testing and laboratory analysis work includes customers in the biotechnology, aquaculture, and food & drug industries.
The combination of exhaustive internal testing procedures to monitor sanitation as well as crop microbial contamination and third party external testing for verification has produced a multi-layer process to ensure ABcann’s Quality Assurance program goals are met and exceeded.
Original press release: https://globenewswire.com/news-release/2017/04/24/970264/0/en/Panda-and-ABcann-Medicinals-Announce-Multi-Stage-Product-Testing-Methodology.html?ev=1
